Filing Flows › Health Care › DBV Technologies S.A. (DBVT)
DBV Technologies S.A. (DBVT) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 28, 2026 · DBV Technologies S.A. (DBVT) Q3 2026 earnings results →
Q3 2026 Revenue down 43% year over year to $1.6M
DBV Technologies S.A. made $1.6M in Q3 2026 (-43% Y/Y). Operating margin n/m, net loss $64.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 28, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.6M in Q3 2026, down 43% year over year and up 129% from the previous quarter.
Operating costs exceeded revenue by $64.8M, an operating margin of -4050.0%. Total costs grew 79% against a revenue fall of 43%. The fastest-growing cost line was Sales & marketing (+342%). The quarter ended with a net loss of $64.5M, wider than the previous quarter's $50.4M loss.
Operating cash flow was −$51.5M. Non-cash charges added back $600K of depreciation and amortization and $4.9M of share-based compensation. Working capital and other items added $7.5M. Capital expenditures of $2.2M exceeded it, leaving free cash flow of −$53.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 28, 2026 | $1.6M | -43% | n/m | −$64.5M | −$51.5M |
| Q2 2026 | 10-Q | Jul 16, 2026 | $700K | -53% | n/m | −$50.4M | −$52.6M |
| Q1 2026 | 10-Q | Apr 30, 2026 | $900K | +12% | n/m | −$47.6M | −$49.1M |
| Q4 2025 | 10-K | Mar 26, 2026 | $636K | +24% | n/m | −$44.8M | −$35.2M |
| Q3 2025 | 10-Q | Oct 28, 2025 | $2.8M | +161% | n/m | −$33.2M | −$32.4M |
| Q2 2025 | 10-Q | Jul 29, 2025 | $1.5M | +29% | n/m | −$41.9M | −$33.9M |
| Q1 2025 | 10-Q | Apr 30, 2025 | $753K | -46% | n/m | −$27.1M | −$19.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About DBV Technologies S.A.
DBV Technologies is a late-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). We have generated significant data demonstrating that Viaskin patch’s mechanism of action is novel and differentiated. Viaskin patch targets antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph nodes in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body.
In its own words, from its 10-K, filed Mar 26, 2026.
DBV Technologies S.A. against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -43% against the peers' median +11%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| DBVT DBV Technologies S.A. | Q3 2026 | $1.6M | -43% | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: DBV Technologies S.A. 10-Q on SEC EDGAR · CIK 1613780 · Biological Products, (No Diagnostic Substances)
13F: who owns DBVT and who is buying
More on DBVT
- How DBV Technologies S.A. makes money: revenue by segment
- DBV Technologies S.A. next earnings date and what analysts expect
- DBV Technologies S.A. stock forecast, price target and fair value
- Who owns DBV Technologies S.A. stock: holders, funds and Congress trades
- DBV Technologies S.A. recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results